Abstract
Cancer of the prostate has been propelled into the limelight of the American public for many reasons. It the most common internal cancer in men (followed only by lung cancer) and the second most common cancer death (second only to lung cancer). There are many reasons for the apparent increase in the incidence of prostate cancer. The population expansion coupled by increasing life expectancy and dramatic improvement in the technologies to diagnose prostate cancer made this disease a target not only by the scientific community but by the lay public as well. The objective of this chapter is to review the basic information and present the most recent advances regarding prostatic carcinoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA 1990; 210: 9
Scardino PT. What is the rationale for treating localized prostate cancer? AUA Today 1995; 8: 10
Gilliland FD, Becker TM, Key CR, et al. Contrasting trends of prostate cancer incidence and mortality in New Mexico’s Hispanics, non-Hispanic Whites, American Indians and Blacks. Cancer 1994; 73: 2192–2199
Taylor JD, Holmes TM, Swanson GM. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994; 73: 1704–1707
Devesa SS, Silvermanø DT, Young JL Jr, et al. Cancer incidence and mortality trends among Whites in the United States, 1947-84. J Natl Cancer Inst 1987; 79: 701–770.
Ernster VL, Winkelstein W Jr, Selvin S, et al. Race, socioeconomic status, and prostate cancer. Cancer Treat Rep 1977; 61: 187–191
Hirst AE, Bergman AT. Carcinoma of the prostate in men 80 or more years old. Cancer 1954; 7: 136–141
Aprikian AG, Zhang ZF, Fair WR. Prostate adenocarcinoma in men younger than 50 years: a retrospective review of 151 patients. Cancer 1994; 74: 1768–1777
Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 337
Aprikian AG, Bazinet M, Plante M, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995; 154: 404–406
Moore RA. Endocrinology of Neoplastic Disease. New York, Oxford University Press, 1947
Kolonel LN, Hankin JH, Nomura AMY, et al. Studies of nutrients and their relationship to cancer in the multiethnic population of Hawaii. Adv Exp Med Biol 1986; 206: 35–43
Carroll KK, Kohr HT. Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 1975; 10: 308–353
McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 619–633
Gleason DF. Histologic grading and staging of prostate of prostatic carcinoma. In: Tannenbaum M (ed). Urologic Pathology: the Prostate. Philadelphia, Lea & Febiger, 1977: 171–179
Winkler HZ, Rainwater LM, Myers RP, et al. Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 1988; 63: 103–112
Stephenson RA, James BC, Gay H, et al. Flow cytometry of prostate cancer: relationship of DNA content to survival. Urol Radiol 1987; 47: 2504–2509
Carmichael MJ, Veltri RW, Partin AW, et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 1015–1019
Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151: 1291–1295
Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283–1290
Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146–1154
Feightner JW. The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the periodic health examination. J Urol 1994; 152: 1682–1684
Stamey TA. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol 1989; 10: 50
Oesterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology 1995; 46: 26–33
Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 1160–1163
Bretton PR, Evans WP, Borden JD, et al. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostatic carcinoma. Cancer 1994; 74: 2991–2995
Cookson MS, Floyd MK, Ball TP Jr, et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 1995; 154: 1070–1073
Carter HB, Pearson JE, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–2220
Catalona WJ, Smith DS, Ratliff TL. Value of measurements of the rate of change on serum PSA levels in prostate cancer screening. J Urol 1993; 149: 300A
Brawer MK. Screening for prostate cancer. Monogr Urol 1994; 15: 1–24
Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 3l7: 909–916
Zagars GK, von Eschenbach AC. Prostate specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993; 72: 538–548
Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151: 640–645
Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1856–1859
Ritter MA, Messing EM, Shanahan TG, et al. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10: 1208–1217
Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichy-motrypsin is the major form of the prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Urol Radiol 1991; 51: 222–226
Oesterling JE, Jacobsen SJ, Klee GG, et al. Free complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–1095
Catalona WJ, Smith DS, Wolfert RL, et al. Increased specificity of PSA screening through measurement of percent free PSA in serum. J Urol 1995; 153: 312A
Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71–75
Chybowski FM, Larson-Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313–318
Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993: its limited clinical utility. Urol Clin North Am 1993; 20: 589–595
Levran Z, Gonzalez JA, Diokno AC, et al. Are pelvic computed tomography, bone scan and pelvic lymphadenec-tomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778–781
Outwater EK, Peterson RO, Siegelman ES, et al. Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994; 193: 333–339
Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of radiology diagnostic oncology group comparison of three MR imaging techniques. Radiology 1994; 192: 47–54
Bluestein DL, Bostwick DG, Bergstralh EJ, et al. Eliminating the need for bilateral pelvic lymphadenectomy in selec_ patients with prostate cancer. J Urol 1994; 151: 1315–1320
Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 713–725
Middleton RG, Thompson IM, Austenfeld MS, et al. The Management of Localized Prostate Cancer: A Patient’s Guide. American Urological Association, Baltimore, 1995
Adolfsson J, Ronstrom L, Lowhagen T, et al. Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol 1994; 152: 1757–1760
Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154: 424–428
Hanks GE, Hanlon A, Schultheiss T, et al. Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformai radiation and adjuvant androgen deprivation. J Urol 1994; 152: 1775–1780
Eisbruch A, Perez CA, Roesler EH, et al. Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer 1994; 73: 384–388
Cookson MS, Sarosdy ME Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J 1994; 87: l–6
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Diokno, A.C., Gonzalez, J.A. (1998). Malignancy of the Prostate Gland. In: Jafri, S.Z.H., Diokno, A.C., Amendola, M.A. (eds) Lower Genitourinary Radiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1648-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4612-1648-3_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7230-4
Online ISBN: 978-1-4612-1648-3
eBook Packages: Springer Book Archive